Trade Pfizer Inc. with LHFX

Pfizer is one of the largest pharmaceutical companies in the world by revenue, with around $63 billion in annual sales across two reporting segments since the post-COVID restructuring: Biopharma (essentially all of revenue) and an emerging contribution from the late-2023 acquisition of Seagen, the oncology antibody-drug-conjugate (ADC) specialist purchased for $43 billion. The equity story is dominated by the COVID-19 revenue cliff. Comirnaty (the BNT162b2 mRNA vaccine, co-developed with BioNTech) and Paxlovid (the oral antiviral) generated combined revenue above $56 billion in 2022. By 2024 that combined COVID-related revenue had fallen below $11 billion as government contract revenue collapsed and the market shifted to private-sector commercial purchasing at lower volumes. The non-COVID base business has been growing in line with most large-cap pharma at low to mid single digits, but the overall reported revenue line has fallen sharply. The Seagen acquisition brings four marketed ADCs (Adcetris in lymphoma, Padcev in urothelial cancer, Tukysa in HER2-positive breast cancer, Tivdak in cervical cancer) and a deep pipeline. Oncology is the largest single therapeutic area at Pfizer post-Seagen, with key franchises in breast cancer (Ibrance), prostate cancer (Xtandi), and now ADCs. The other pillars are vaccines (Prevnar, Abrysvo for RSV), internal medicine (Eliquis, the cardiovascular blockbuster co-developed with Bristol-Myers Squibb), immunology (Litfulo, Cibinqo), and rare disease. At LHFX you trade PFE as a CFD on the Pfizer share price. You profit or lose based on price movement and can go long or short. You do not own the share, have no voting rights, and dividends are passed through as a dividend adjustment on the ex-date. Maximum leverage on US single-stock CFDs is 1:20. Spreads are raw with a $3 per side commission. Pfizer has paid a dividend for over 35 years and pays around 42 cents per share quarterly. The dividend yield is elevated versus large-cap pharma peers, reflecting the post-COVID revenue compression and a stretched payout ratio.

Open an LHFX account, complete verification, and fund it from $10. Search PFE in MetaTrader 5 or LHFX Trade. US cash hours apply: 14:30 to 21:00 UTC, Monday to Friday. CFDs pay a daily swap on positions held overnight, and dividends are passed through as a dividend adjustment on the ex-date. PFE has been higher volatility than the typical large-cap pharma name since the 2022 to 2023 COVID cliff. Average daily range has run around 1.5 to 2.0%, with major news (COVID guidance updates, Seagen acquisition close, pipeline readouts) producing 5 to 10% single-day moves. Illustrative sizing at a $28 share price: a 100-share PFE position is $2,800 of notional and requires $140 of margin at 1:20 leverage. A 5% adverse move costs $140, your entire margin. Round-trip commission on 100 shares is $6. PFE reports earnings early February, late April or early May, late July or early August, and late October or early November before the US market open. Implied moves on earnings have run 4 to 7% since the COVID revenue volatility. Medical conferences (ASCO in early June, ESMO in September, ASH in December) are scheduled platforms for oncology data readouts on Padcev, Adcetris, Tukysa, and Pfizer's broader ADC and immuno-oncology pipeline post the Seagen acquisition. These dates produce news flow outside earnings windows. The ex-dividend date is typically late January, early May, early August, and early November. Set a stop loss before entry. For a $1,500 account risking $30 per trade at a $0.30 stop distance, position size is 100 shares.